Moberg Pharma’s Nomination Committee appointed
STOCKHOLM, October 17th, 2023 – In accordance with the resolution of the Annual General Meeting on May 16th, 2023, the Chairman of the Board has contacted the company’s two largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s two largest shareholders or group of shareholders have wished to appoint such representative, the third largest shareholder/group of shareholders have been invited to appoint one representative and so on until the Nomination Committee now comprises of three members, in accordance with the resolution of the Annual General Meeting on May 16th, 2023.
Moberg Pharma’s Nomination Committee ahead of the Annual General Meeting for the fiscal year January – December 2023 comprises:
- Gillis Cullin, appointed by Östersjöstiftelsen
- Ida Marie Lindberg, appointed by Kjelsmark Holding
- Kerstin Valinder Strinnholm, Chairman of the Board
Together, the Nomination Committee represents 17.3 percent of the shares in Moberg Pharma as of September 29th, 2023.
The Nomination Committee shall submit proposals for the fiscal year January – December 2023 by the Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.
The Annual General Meeting for the fiscal year January – December 2023 will be held on May 14th 2024.
Shareholders wishing to submit proposals to Moberg Pharma’s Nomination Committee can do so by e-mail to info@mobergpharma.se by March 26th, 2024.
About this information
The information was submitted for publication, through the agency of the contact person set out below, at 8.30 a.m. CET on October 17th, 2023.
For additional information, please contact:
Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: anna.ljung@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis, for which market approvals in several EU-countries has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the Company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).